Home › Funds › Ikarian Capital, LLC › MAZE
Ikarian Capital, LLC position in MAZE
MAZE THERAPEUTICS INC · Health Care
Ikarian Capital, LLC reported holding 378,999 shares of MAZE (MAZE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$11.3M, representing 1.82% of its reported portfolio and ranking #13 among its reported holdings. Ikarian Capital, LLC has disclosed MAZE holdings in 6 of the last 6 reported quarters, going back to Q1 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Ikarian Capital, LLC's MAZE position evolved
Ikarian Capital, LLC first disclosed a stake in MAZE in Q1 2025 at 322,740 shares (US$3.6M). The position peaked in Q4 2025 at 644,680 shares, worth US$26.7M. Across 6 filings, Ikarian Capital, LLC increased the stake 2 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 378,999 shares valued at US$11.3M — an increase of 364,599 shares quarter over quarter.. Notable position changes include a 182% increase in Q3 2025 (shares rose 60% over the following quarter), a 98% trim in Q1 2026 (shares were roughly flat over the following quarter), a 2532% increase in Q2 2026 (shares fell 9% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2025 | 322.74K | $3.55M | New |
| Q2 2025 | 262.74K | $3.22M | Reduce |
| Q3 2025 | 740.83K | $19.21M | Add |
| Q4 2025 | 644.68K | $26.71M | Reduce |
| Q1 2026 | 14.40K | $429.84K | Reduce |
| Q2 2026 | 379.00K | $11.31M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MAZE and 13F data
MAZE (MAZE THERAPEUTICS INC) is a Health Care company. 74 other funds we track also report a position in MAZE — the largest reported positions include Frazier Life Sciences Management, L.P. (US$150.2M), TRV GP IV, LLC (US$133.5M), ARCH Venture Management, LLC (US$123.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MAZE
- Frazier Life Sciences Management, L.P. 5.03M sh · $150.18M · Q2 2026
- TRV GP IV, LLC 4.47M sh · $133.50M · Q2 2026
- ARCH Venture Management, LLC 4.12M sh · $122.98M · Q2 2026
- Deep Track Capital, LP 3.73M sh · $111.38M · Q2 2026
- Logos Global Management LP 1.94M sh · $57.74M · Q2 2026
- a16z Capital Management, L.L.C. 1.70M sh · $50.79M · Q2 2026
- Venrock Adviser, LLC 1.60M sh · $47.80M · Q2 2026
- Alphabet Inc. 1.39M sh · $41.44M · Q2 2026
- BRAIDWELL LP 1.14M sh · $34.02M · Q2 2026
- Farallon Capital Management 1.11M sh · $33.06M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 1.11M sh · $33.06M · Q2 2026
- General Catalyst Group Management, LLC 1.04M sh · $30.91M · Q2 2026
More on Ikarian Capital, LLC
FAQ
How long has Ikarian Capital, LLC held MAZE?
Ikarian Capital, LLC has disclosed MAZE holdings in 6 of the last 6 reported quarters, going back to Q1 2025.
What is Ikarian Capital, LLC's current position in MAZE?
As of Q2 2026, Ikarian Capital, LLC holds 379.00K shares of MAZE (MAZE THERAPEUTICS INC), valued at $11.31M, representing 1.82% of its reported portfolio and ranking #13.
Has Ikarian Capital, LLC been buying or selling MAZE?
In the latest 13F filing (Q2 2026), Ikarian Capital, LLC increased its position in MAZE. The position peaked in Q4 2025 at 644.68K shares.
Which other funds hold MAZE?
Other major institutional holders of MAZE include Frazier Life Sciences Management, L.P., TRV GP IV, LLC, ARCH Venture Management, LLC, among 74 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.